Humanwell Healthcare's US Unit Gains FDA Approval for OTC Painkiller
Tang Shihua
DATE:  Mar 20 2018
/ SOURCE:  Yicai
Humanwell Healthcare's US Unit Gains FDA Approval for OTC Painkiller Humanwell Healthcare's US Unit Gains FDA Approval for OTC Painkiller

(Yicai Global) March 20 -- A unit of Chinese pharmaceutical manufacturer Humanwell Healthcare Group Co. has received the green light from US regulators to produce and sell an over-the-counter generic painkiller drug in the country. 

Puracap Pharmaceutical LLC., in which Wuhan-based Humanwell Healthcare holds a 72 percent stake, has received approvals from the US Food and Drug Administration for naproxen sodium capsule, the company said in a statement.

The approvals will have a positive effect on the firm's efforts to expand in the US market, and Puracap will actively prepare for the product's release. US pharmaceutical manufacturer Bionpharma Inc. achieved sales of naproxen sodium capsule totaling around USD60 million in 2017, while sales of the drug in Chinese public hospitals came to CNY100 million in 2016.

The drug is mainly used to relieve pain, fever and inflammation at various levels, as well as ankylosing reactions caused by rheumatic arthritis, rheumatoid arthritis, and gout, the statement said.

Puracap invested USD1 million in the research and development of naproxen sodium capsule in 2016.

Follow Yicai Global on
Keywords:   FDA Approved,US Market,Generic Drug,Humanwell Healthcare